Pacer Advisors Portfolio holdings
AUM
$39.6B
1-Year Return
5.04%
This Quarter Return
+6.36%
1 Year Return
+5.04%
3 Year Return
+42.86%
5 Year Return
+91.64%
10 Year Return
+332.32%
AUM
$5.75B
AUM Growth
+$430M
(+8.1%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-18.82%
Top 10 Holdings %
Top 10 Hldgs %
27.15%
Holding
1,587
New
76
Increased
379
Reduced
937
Closed
183
Top Buys
| 1 |
HP
HPQ
|
+$6.72M |
| 2 |
Newmont
NEM
|
+$6.32M |
| 3 |
General Mills
GIS
|
+$6.24M |
| 4 |
TJX Companies
TJX
|
+$5.82M |
| 5 |
Ford
F
|
+$5.76M |
Top Sells
| 1 |
Iron Mountain
IRM
|
+$16.2M |
| 2 |
Apple
AAPL
|
+$15.9M |
| 3 |
Amazon
AMZN
|
+$14.5M |
| 4 |
Microsoft
MSFT
|
+$13.1M |
| 5 |
GDS Holdings
GDS
|
+$7.93M |
Sector Composition
| 1 | Real Estate | 17.47% |
| 2 | Technology | 14.61% |
| 3 | Consumer Discretionary | 9.29% |
| 4 | Healthcare | 7.36% |
| 5 | Communication Services | 6.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Arcus Biosciences
RCUS
$1.22B
| $60K | ﹤0.01% |
2,145
+66
| +3% | +$1.85K |
|
1277
Xencor
XNCR
$606M
| $60K | ﹤0.01% |
1,390
-292
| -17% | -$12.6K |
|
|
TCRR
1278
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $60K | ﹤0.01% |
2,705
+1,624
| +150% | +$36K |
|
1279
Precigen
PGEN
$1.23B
| $60K | ﹤0.01% |
8,708
+5,202
| +148% | +$35.8K |
|
|
ATNX
1280
DELISTED
Athenex, Inc. Common Stock
ATNX
| $60K | ﹤0.01% |
702
+489
| +230% | +$41.8K |
|
1281
Alector
ALEC
$290M
| $59K | ﹤0.01% |
2,918
-1,636
| -36% | -$33.1K |
|
1282
Celldex Therapeutics
CLDX
$1.67B
| $58K | ﹤0.01% |
2,828
-828
| -23% | -$17K |
|
1283
Scholar Rock
SRRK
$3.06B
| $58K | ﹤0.01% |
1,138
+662
| +139% | +$33.7K |
|
1284
Black Diamond Therapeutics
BDTX
$192M
| $57K | ﹤0.01% |
2,369
+1,276
| +117% | +$30.7K |
|
1285
Travere Therapeutics
TVTX
$2.23B
| $57K | ﹤0.01% |
2,293
+744
| +48% | +$18.5K |
|
|
HEP
1286
DELISTED
Holly Energy Partners, L.P.
HEP
| $57K | ﹤0.01% |
2,984
+291
| +11% | +$5.56K |
|
|
EPZM
1287
DELISTED
Epizyme, Inc
EPZM
| $56K | ﹤0.01% |
6,390
+882
| +16% | +$7.73K |
|
1288
Adverum Biotechnologies
ADVM
$65.9M
| $56K | ﹤0.01% |
570
+35
| +7% | +$3.44K |
|
1289
Y-mAbs Therapeutics
YMAB
$390M
| $55K | ﹤0.01% |
1,812
+1,048
| +137% | +$31.8K |
|
1290
Ocugen
OCGN
$334M
| $53K | ﹤0.01% |
+7,800
| New | +$53K |
|
1291
Teladoc Health
TDOC
$1.37B
| $52K | ﹤0.01% |
285
-1,254
| -81% | -$229K |
|
1292
CEL-SCI Corp
CVM
$67.7M
| $51K | ﹤0.01% |
113
+28
| +33% | +$12.6K |
|
1293
Viking Therapeutics
VKTX
$2.89B
| $51K | ﹤0.01% |
8,140
-232
| -3% | -$1.45K |
|
1294
Rigel Pharmaceuticals
RIGL
$678M
| $50K | ﹤0.01% |
1,464
+199
| +16% | +$6.8K |
|
|
TBIO
1295
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $50K | ﹤0.01% |
3,006
-634
| -17% | -$10.5K |
|
1296
Curis
CRIS
$22.7M
| $49K | ﹤0.01% |
+217
| New | +$49K |
|
1297
Keros Therapeutics
KROS
$640M
| $49K | ﹤0.01% |
790
+358
| +83% | +$22.2K |
|
1298
Nurix Therapeutics
NRIX
$703M
| $49K | ﹤0.01% |
1,581
+1,042
| +193% | +$32.3K |
|
1299
Prelude Therapeutics
PRLD
$68.5M
| $49K | ﹤0.01% |
+1,126
| New | +$49K |
|
1300
Catalyst Pharmaceutical
CPRX
$2.48B
| $47K | ﹤0.01% |
10,206
+1,598
| +19% | +$7.36K |
|